Skip to main content
Back
Watch Compare

cbdMD, Inc.

Data quality: 100%
YCBD
NYSE Manufacturing Chemicals
$0.74
▼ $0.01 (-1.34%)
6 months return
—
Momentum
Neutral
5Y revenue growth
-18.95%

Growth

Revenue Growth (5Y)
-18.95%
Below sector avg (1.72%)
Revenue (1Y)-1.50%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-60.24%
Below sector avg (-54.68%)
ROIC-46.31%
Net Margin-10.63%
Op. Margin-11.27%

Safety

Debt / Equity
N/A
Current Ratio1.56
Interest Coverage-63.03

Valuation

PE (TTM)
-3.45
Below sector avg (-1.49)
P/B Ratio1.15
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Revenue declined -18.95% annually over 5 years
Negative free cash flow of -1.64 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 17.45%
Capital efficient — spends only 0.96% of revenue on capex

Price History

Financial Trends

Analyst Price Target

1 analyst
Strong Buy
+171.4%
upside to target
Current
$0.74
Consensus Target
$2.00
$2.00
Low
$2.00
High
Forecast
Forward EPS
-$0.07
Est. Revenue
22.69 M

Earnings Surprises

EPS
Reported Estimate Forecast
Next: Q1 2026 · EPS Est: -$0.05 · Rev Est: 5.29 M
Q12025 Q22025 Q32025 Q42025 Q1 '26 Q2 '26
Reported -$1.90 -$0.21 — -$0.04 — —
Estimate -$1.60 -$0.16 -$0.07 -$0.06 -$0.05 -$0.04
Surprise -18.75% -31.25% — +33.33% — —

Growth

Rev 5Y: -18.95% · Earnings 1Y: N/A
Revenue Growth (1Y) -1.50% Revenue Growth (3Y) -10.87%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -18.95% Earnings Growth (5Y) N/A

Profitability

ROE: -60.24% · Net Margin: -10.63%
Revenue (TTM) 19.19 M Net Income (TTM) -2.04 M
ROE -60.24% ROA -19.59%
Gross Margin 62.37% Operating Margin -11.27%
Net Margin -10.63% Free Cash Flow (TTM) -1.64 M
ROIC -46.31% FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 1.56
Debt / Equity N/A Current Ratio 1.56
Interest Coverage -63.03 Asset Turnover 1.84
Working Capital 2.01 M Tangible Book Value 3.79 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -3.45 · EV/EBITDA: N/A
P/E Ratio -3.45 Forward P/E N/A
P/B Ratio 1.15 P/S Ratio 0.37
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 0.31 Fwd Earnings Yield N/A
FCF Yield -23.27%
Market Cap 7.03 M Enterprise Value 5.97 M

Per Share

EPS: -1.09 · FCF/Share: -0.16
EPS (Diluted TTM) -1.09 Revenue / Share 1.83
FCF / Share -0.16 OCF / Share -0.14
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 80.19% · CapEx/Rev: 0.96%
CapEx / Revenue 0.96% FCF Conversion 80.19%
SBC-Adj. FCF N/A Growth Momentum 17.45

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 19.19 M 19.48 M 24.16 M 35.40 M 44.48 M
Net Income -2.04 M -3.70 M -22.94 M -70.08 M -23.39 M
EPS (Diluted) -1.09 -1.79 -13.32 -1.24 -0.47
Gross Profit 11.97 M 12.00 M 14.98 M 22.34 M 29.99 M
Operating Income -2.16 M -3.32 M -22.49 M -78.27 M -19.62 M
EBITDA — — — — —
R&D Expenses — — — — —
SG&A Expenses — — — — —
D&A — — — — 1.02 M
Interest Expense 34,308.0 -29,507.0 63,702.0 16,246.0 -28,930.0
Income Tax 0.0 0.0 0.0 0.0 895,000.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 10.42 M 10.58 M 16.20 M 40.79 M 124.88 M
Total Liabilities 3.19 M 8.62 M 7.16 M 9.37 M 21.74 M
Shareholders' Equity 7.23 M 1.96 M 9.03 M 31.42 M 103.14 M
Total Debt — — 9.0 125,491.0 108,985.0
Cash & Equivalents 2.26 M 2.45 M 1.80 M 6.72 M 26.41 M
Current Assets 6.55 M 6.39 M 8.07 M 16.01 M 36.50 M
Current Liabilities 3.19 M 8.62 M 4.67 M 5.29 M 6.92 M

Peer Comparison

vs Manufacturing sector median (1605 peers)
Metric Stock Sector Median
P/E -3.5 -1.5
P/B 1.2 1.6
ROE % -60.2 -54.7
Net Margin % -10.6 -41.5
Rev Growth 5Y % -19.0 1.7
D/E — 0.3